Panavance Therapeutics

Pancreatic cancer
#Oncology #Panavance Therapeutics #Pancreatic cancer #Phase I trial

Interim data reveals potential of new pancreatic cancer drug

Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma. Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The… Read More

#Cancer Research #News

Ovarian cancer cells
#Oncology #Panavance Therapeutics #PARP inhibitors #Preclinical development

New data support antitumour drug misetionamide in ovarian cancers

New published data have demonstrated positive monotherapy results for misetionamide as well as synergistic activity with PARP inhibitors (PARPis) and bevacizumab antineoplastic in ovarian cancer. Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models. Misetionamide’s inhibition… Read More

#Cancer Research #News